OWLT Stock Analysis: Buy, Sell, or Hold?
OWLT - Owlet, Inc.
$5.09
-0.05 (-0.97%)
▼
5d:
-0.39%
30d:
-57.01%
90d:
-68.25%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When OWLT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OWLT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: OWLT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: OWLT is currently trading at $5.09, which is considered slightly low relative to its 30-day fair value range of $4.50 to $10.39. From a valuation perspective, the stock is trading at a premium (Forward PE: 56.6) compared to its historical average (38.6). At these levels, the market is pricing in 13.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OWLT is in a strong downtrend. Immediate support is located at $4.43, while resistance sits at $5.44.
Market Sentiment: OWLT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.25 (+180.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OWLT is in a strong downtrend. Immediate support is located at $4.43, while resistance sits at $5.44.
Market Sentiment: OWLT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.25 (+180.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.50 -
$10.39
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.0% below Wall St target ($14.25)
- NEUTRAL: Trading at premium valuation - market expects 13.6% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$4.50 -
$10.39
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.43
Resistance Level
$5.44
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
56.56
Wall Street Target
$14.25
(+180.0%)
Revenue Growth (YoY)
29.6%
Profit Margin
-37.5%
Valuation Premium vs History
+13.6% premium
PE vs Historical
56.6 vs 38.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.6%
(market-implied from PE analysis)
1-Year Target
$5.78
(+14%)
2-Year Target
$6.57
(+29%)
3-Year Target
$7.46
(+47%)
3-Yr Target (if PE normalizes)
(PE: 57→39)
PE COMPRESSION
$5.09
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: April 02, 2026 4:26 AM ET
Data refreshes hourly during market hours. Next update: 5:26 AM
Data refreshes hourly during market hours. Next update: 5:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OWLT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Amanda Crawford
SELL
183 shares
2026-01-20
Jonathan Harris
SELL
2311 shares
2026-01-20
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 61 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 54 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 49 HOLD |
